Maiso et al. showed that targeting lactate dehydrogenase A (LDHA) and hypoxia-inducible factor alpha (HIF1α) resensitized myeloma to bortezomib and could impair tumor growth [15]. The gene discussed is LDHA; the disease is plasma cell myeloma.